GABRG2 rs6060371: Understanding Genetic Epilepsy Associations
The rs6060371 variant is located within the GABRG2 gene, which provides instructions for creating a critical component of GABA-A receptors in the brain. This variant is studied for its potential role in genetic epilepsy with febrile seizures plus (GEFS+), a condition characterized by a spectrum of seizure types.
What each genotype means
Typical GABRG2 profile
This genotype represents the most common version of the GABRG2 gene found in the general population. It is not associated with the specific pathogenic variants linked to genetic epilepsy with febrile seizures plus (GEFS+) or other related epilepsy syndromes. This result does not rule out the presence of other genetic or environmental factors that may influence seizure risk.
This is the most common genotype observed across all major global populations.
Requires clinical evaluation
This genotype indicates the presence of one copy of the variant allele. While GABRG2 variants are known to be associated with a spectrum of epilepsy syndromes, the clinical significance of this specific variant depends on its functional impact on the GABA-A receptor. You should discuss this finding with a genetic counselor or neurologist to determine if it is relevant to your personal or family health history.
This genotype is rare in the general population, with specific frequencies varying significantly by ancestry.
Requires clinical evaluation
This genotype indicates the presence of two copies of the variant allele. Because GABRG2 variants can be associated with a wide range of epilepsy phenotypes, including febrile seizures and more severe developmental conditions, this result warrants professional medical review. Please consult with a healthcare provider to interpret this finding in the context of your clinical presentation.
This genotype is extremely rare in the general population.
What is the rs6060371 Variant?
The rs6060371 variant is a single nucleotide polymorphism (SNP) situated within the GABRG2 gene. In genomics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region of the genome that influences the expression or function of the gamma-2 subunit of the GABA-A receptor. Researchers track such variants to understand how subtle differences in our genetic code might contribute to neurological conditions. While many SNPs are neutral, those located in genes critical to brain function, like GABRG2, are of particular interest to scientists investigating the biological underpinnings of epilepsy and other seizure-related disorders.
The Role of the GABRG2 Gene
The GABRG2 gene encodes the gamma-2 subunit of the GABA-A receptor, which is the primary inhibitory neurotransmitter receptor in the human brain. These receptors act like a 'brake' system for the nervous system, helping to regulate electrical activity and prevent over-excitation of neurons. When the GABRG2 gene is altered, the resulting GABA-A receptors may not function correctly, potentially leading to an imbalance between excitatory and inhibitory signals. This imbalance is a hallmark of various epilepsy syndromes. Because the gamma-2 subunit is essential for the proper trafficking and formation of these receptor channels, variants in this gene can have significant impacts on how effectively the brain manages its electrical signaling.
Research and Clinical Associations
Research has established a strong link between GABRG2 variants and a spectrum of epilepsy syndromes, most notably genetic epilepsy with febrile seizures plus (GEFS+). While rare, highly penetrant mutations in this gene are known to cause severe forms of epilepsy, the role of common variants like rs6060371 is more complex. Some studies suggest that common variation in GABRG2 may contribute to susceptibility in complex, polygenic forms of epilepsy, though results across different cohorts have been mixed. It is important to note that the presence of a variant does not guarantee the development of a condition; rather, it represents a statistical association observed in population studies. The evidence strength for GABRG2 as a risk gene is considered strong, but the specific contribution of rs6060371 is part of an ongoing area of investigation.
Population Frequency
The rs6060371 variant is classified as a common variant, meaning it is found at a relatively high frequency across diverse human populations. Because it is common, it is present in many healthy individuals who do not exhibit any signs of epilepsy or seizure disorders. This high frequency suggests that the variant alone is likely not sufficient to cause disease and may only act as a minor risk factor or a neutral genetic marker in the general population. Geneticists often compare the frequency of such variants in large control groups versus groups with specific clinical diagnoses to determine if there is a statistically significant difference in prevalence.
Interpreting Your Genetic Information
If you have information about your rs6060371 genotype, it is important to understand that this data is for educational purposes only. A genetic variant is just one piece of a much larger puzzle that includes other genetic factors, environmental influences, and individual health history. This information cannot be used to diagnose a medical condition or predict future health outcomes. If you have concerns about epilepsy, seizures, or your family medical history, you should consult with a qualified healthcare professional or a genetic counselor. They can provide context based on your specific clinical situation and help you understand what, if any, further steps are appropriate for your health management.
How common is this variant?
The rs6060371 variant is common across global populations, appearing frequently in both healthy individuals and those with various clinical backgrounds.
Frequently asked questions
Does having the rs6060371 variant mean I will develop epilepsy?
No. Having this variant does not mean you will develop epilepsy. It is a common genetic marker, and most people who carry it do not have any seizure-related conditions.
What is the link between GABRG2 and febrile seizures?
GABRG2 variants are known to be associated with genetic epilepsy with febrile seizures plus (GEFS+). This condition involves seizures that are triggered by fevers, often persisting beyond early childhood.
Can I use this information to change my medication?
No. You should never change or stop any medication based on genetic information without first consulting your doctor or pharmacist. They are the only ones who can safely manage your treatment plan.
Is rs6060371 considered a 'disease-causing' mutation?
No. rs6060371 is a common SNP, not a rare, highly penetrant mutation. While some rare mutations in GABRG2 are directly causative of epilepsy, common variants like this one are generally considered to have a much smaller or neutral effect.
Sources & further reading
Educational information only, last refreshed 10/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6060371?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in GABRG2
This variant in the GABRG2 gene is associated with variations in response to certain anticonvulsant medications and epilepsy susceptibility.
This variant is located in the GABRG2 gene, which encodes the gamma-2 subunit of the GABA-A receptor; variants in this gene are associated with a spectrum of epilepsy syndromes.
Linked to GABA-A receptor subunit dysfunction, a known mechanism for inherited epilepsy syndromes.
A common variant in GABRG2, a gene encoding a GABA-A receptor subunit linked to various epilepsy phenotypes including febrile seizures and GEFS+.
Variant in GABRG2, a gene where mutations can alter GABA-A receptor function and influence seizure thresholds.
Mutations in GABRG2 are linked to a spectrum of epilepsy ranging from simple febrile seizures to severe developmental and epileptic encephalopathies.